Gilead Sciences, Inc. $GILD Shares Bought by Conning Inc.

Conning Inc. grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.9% during the 2nd quarter, HoldingsChannel reports. The firm owned 318,581 shares of the biopharmaceutical company’s stock after buying an additional 5,854 shares during the period. Conning Inc.’s holdings in Gilead Sciences were worth $35,321,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Smallwood Wealth Investment Management LLC acquired a new stake in Gilead Sciences during the 1st quarter worth $25,000. Activest Wealth Management boosted its stake in Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the last quarter. Goodman Advisory Group LLC acquired a new stake in Gilead Sciences during the 1st quarter worth $29,000. Colonial Trust Advisors boosted its stake in Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 213 shares during the last quarter. Finally, Core Alternative Capital boosted its stake in Gilead Sciences by 370.8% during the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 241 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Trading Up 0.4%

NASDAQ GILD opened at $117.18 on Friday. The firm’s 50-day moving average is $114.65 and its two-hundred day moving average is $110.25. Gilead Sciences, Inc. has a 12 month low of $84.17 and a 12 month high of $121.83. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The stock has a market capitalization of $145.40 billion, a P/E ratio of 23.34, a PEG ratio of 0.79 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. During the same quarter in the prior year, the company posted $2.01 earnings per share. Gilead Sciences’s revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were given a $0.79 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. Gilead Sciences’s dividend payout ratio is presently 62.95%.

Analyst Ratings Changes

Several equities research analysts have issued reports on GILD shares. Daiwa Capital Markets raised shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price on the stock in a research note on Tuesday, August 19th. UBS Group boosted their price target on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research report on Friday, August 8th. Truist Financial raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and boosted their price target for the company from $108.00 to $127.00 in a research report on Friday, August 8th. Royal Bank Of Canada boosted their price target on shares of Gilead Sciences from $98.00 to $100.00 and gave the company a “sector perform” rating in a research report on Wednesday. Finally, Rothschild & Co Redburn boosted their price target on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a research report on Friday, September 12th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $118.08.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $283,925.00. Following the transaction, the chief financial officer owned 159,555 shares of the company’s stock, valued at $18,120,661.35. This represents a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $109.74, for a total transaction of $548,700.00. Following the sale, the director owned 8,920 shares in the company, valued at $978,880.80. This trade represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 82,000 shares of company stock worth $9,402,130. 0.27% of the stock is owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.